Cassava Sciences (SAVA) Competitors $2.30 +0.09 (+4.07%) Closing price 04:00 PM EasternExtended Trading$2.32 +0.02 (+0.65%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. SNDL, ERAS, CMPX, AQST, ITOS, ETON, VIGL, HUMA, CYRX, and ATXSShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include SNDL (SNDL), Erasca (ERAS), Compass Therapeutics (CMPX), Aquestive Therapeutics (AQST), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Vigil Neuroscience (VIGL), Humacyte (HUMA), CryoPort (CYRX), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Its Competitors SNDL Erasca Compass Therapeutics Aquestive Therapeutics iTeos Therapeutics Eton Pharmaceuticals Vigil Neuroscience Humacyte CryoPort Astria Therapeutics Cassava Sciences (NASDAQ:SAVA) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation. Do analysts recommend SAVA or SNDL? Cassava Sciences currently has a consensus target price of $54.50, suggesting a potential upside of 2,269.57%. SNDL has a consensus target price of $4.00, suggesting a potential upside of 153.16%. Given Cassava Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cassava Sciences is more favorable than SNDL.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50SNDL 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, SAVA or SNDL? Cassava Sciences has higher earnings, but lower revenue than SNDL. SNDL is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$24.34M-$1.50-1.53SNDL$671.81M0.62-$69.18M-$0.29-5.45 Is SAVA or SNDL more profitable? Cassava Sciences has a net margin of 0.00% compared to SNDL's net margin of -11.48%. SNDL's return on equity of -9.02% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -87.72% -72.05% SNDL -11.48%-9.02%-7.60% Which has more risk and volatility, SAVA or SNDL? Cassava Sciences has a beta of -2.04, meaning that its share price is 304% less volatile than the S&P 500. Comparatively, SNDL has a beta of 3.4, meaning that its share price is 240% more volatile than the S&P 500. Do institutionals and insiders hold more shares of SAVA or SNDL? 38.1% of Cassava Sciences shares are held by institutional investors. 12.2% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to SAVA or SNDL? In the previous week, SNDL had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 1 mentions for SNDL and 0 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.00 equaled SNDL'saverage media sentiment score. Company Overall Sentiment Cassava Sciences Neutral SNDL Neutral SummaryCassava Sciences beats SNDL on 8 of the 14 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$106.76M$2.44B$5.52B$9.41BDividend YieldN/A1.80%4.01%4.05%P/E Ratio-1.533.2918.7818.43Price / SalesN/A714.70446.2599.61Price / CashN/A22.4924.9928.17Price / Book0.765.008.145.70Net Income-$24.34M$30.99M$3.24B$257.84M7 Day Performance6.48%1.71%1.12%1.87%1 Month Performance15.58%11.18%8.39%13.28%1 Year Performance-77.18%0.82%34.01%19.15% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences3.8285 of 5 stars$2.30+4.1%$54.50+2,269.6%-78.1%$106.76MN/A-1.5330SNDLSNDL1.274 of 5 stars$1.58+13.7%$3.63+129.4%-25.6%$415.19M$671.81M-5.452,516High Trading VolumeERASErasca2.1353 of 5 stars$1.46+0.7%$4.57+213.1%-49.2%$413.60MN/A-2.35120CMPXCompass Therapeutics2.2653 of 5 stars$2.92+8.1%$12.67+333.8%+220.2%$403.79M$850K-7.1220AQSTAquestive Therapeutics1.2941 of 5 stars$4.03+0.5%$10.14+151.7%+31.3%$400.30M$57.56M-6.83160Positive NewsITOSiTeos Therapeutics2.7642 of 5 stars$10.35+0.6%$15.86+53.2%-34.8%$396.09M$35M-3.4090Trending NewsAnalyst ForecastTrading HaltedETONEton Pharmaceuticals2.4689 of 5 stars$14.54+0.3%$29.67+104.0%+329.1%$389.96M$39.01M-80.7820Analyst RevisionHigh Trading VolumeVIGLVigil Neuroscience3.4064 of 5 stars$8.07+0.2%$10.80+33.8%+116.9%$384.83MN/A-3.9440HUMAHumacyte1.5439 of 5 stars$2.47+6.9%$11.71+374.3%-69.1%$383.14M$517K-3.58150Analyst DowngradeCYRXCryoPort2.6408 of 5 stars$7.50-0.7%$10.88+45.0%-17.1%$376.05M$228.38M-3.211,186Analyst RevisionATXSAstria Therapeutics1.6329 of 5 stars$6.62+3.9%$30.00+353.2%-46.7%$373.57MN/A-3.5430 Related Companies and Tools Related Companies SNDL Competitors Erasca Competitors Compass Therapeutics Competitors Aquestive Therapeutics Competitors iTeos Therapeutics Competitors Eton Pharmaceuticals Competitors Vigil Neuroscience Competitors Humacyte Competitors CryoPort Competitors Astria Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SAVA Stock Alerts